UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx) [Yahoo! Finance]
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: Yahoo! Finance
the United States in a 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX The single-injection device offers convenience for patients requiring a 320 mg dose of BIMZELX with single-injection administration ATLANTA Jan. 16, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX ® (bimekizumab-bkzx) is now available. These are in addition to the currently available 1 mL device administration options, each containing 160 mg of BIMZELX. (PRNewsfoto/UCB, Inc.) With the new presentations, patients requiring a 320 mg dose of BIMZELX will have options for single-injection administration. "With five new FDA-approved indications for BIMZELX in just over a year, we've had the opportunity to reach a wider range of people living with chronic inflammatory conditions who have long been in need of new treatment options," said Camille Lee , Head of
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorderPR Newswire
- UCB shares leading scientific research and advances at American Epilepsy Society Annual MeetingPR Newswire
- UCB (OTCMKTS:UCBJY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)PR Newswire
- UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™PR Newswire